Health care in Iran
下方的详细分析以英文发布。
Iran manufactures the large majority of the medicines it consumes by volume and has built biotech capability in biosimilars and vaccines that is unusual for the region.
The import gap is in high-value therapeutics, advanced medical devices and diagnostics — precisely where a foreign technology partner adds capability rather than competing with domestic producers.
The Iran FDA controls registration, pricing and import licensing for medicines and devices. Registration timelines depend heavily on whether an equivalent domestic product exists — protection of local manufacture is an explicit policy objective.
Local manufacturing or fill-finish partnerships shorten market access considerably compared with a pure import registration.
Imaging, laboratory automation, interventional cardiology and oncology equipment are consistently import-dependent, with service and consumables representing the durable revenue rather than the capital sale.
Distributor selection is the main commercial risk: after-sales service capability, not price, determines whether an installed base grows.
Iran receives significant inbound medical travel from neighbouring countries for surgery, fertility treatment and ophthalmology, driven by cost and clinical reputation.
Investment opportunities lie in hospital capacity, accredited private clinics and the hospitality and coordination layer around them.
Around 95% by volume, though a disproportionate share of value sits in imported high-end therapeutics.
The Iran Food and Drug Administration, which controls registration, pricing and import licensing.
Local manufacturing, licensing or a fill-finish partnership with a registered domestic producer, which typically clears faster than import-only registration.
Yes. Established regional inbound flows support investment in accredited private clinics, hospital capacity and the coordination layer around treatment.